Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Caribou Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Caribou Biosciences, Inc.’s stock price such as:

• Caribou Biosciences, Inc.’s current stock price and volume
• Why Caribou Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for CRBU from analysts
• CRBU’s stock price momentum as measured by its relative strength

About Caribou Biosciences, Inc. (CRBU)

Before we jump into Caribou Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company’s lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Want to learn more about Caribou Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Caribou Biosciences, Inc..

Caribou Biosciences, Inc.’s Stock Price as of Market Close

As of January 16, 2026, 4:00 PM, CST, Caribou Biosciences, Inc.’s stock price was $1.460.

Caribou Biosciences, Inc. is down 6.41% from its previous closing price of $1.560.

During the last market session, Caribou Biosciences, Inc.’s stock traded between $1.450 and $1.570. Currently, there are approximately 93.29 million shares outstanding for Caribou Biosciences, Inc..

Caribou Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Caribou Biosciences, Inc. Stock Price History

Caribou Biosciences, Inc.’s (CRBU) price is currently down 8.18% so far this month.

During the month of January, Caribou Biosciences, Inc.’s stock price has reached a high of $1.800 and a low of $1.450.

Over the last year, Caribou Biosciences, Inc. has hit prices as high as $3.535 and as low as $0.660. Year to date, Caribou Biosciences, Inc.’s stock is down 8.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Caribou Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 16, 2026, there were 0 analysts who downgraded Caribou Biosciences, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Caribou Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Caribou Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Caribou Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Caribou Biosciences, Inc. (CRBU) by visiting AAII Stock Evaluator.

Relative Price Strength of Caribou Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2026, Caribou Biosciences, Inc. has a weighted four-quarter relative price strength of 3.26%, which translates to a Momentum Score of 63 and is considered to be Strong.

Want to learn more about how Caribou Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Caribou Biosciences, Inc. Stock Price: Bottom Line

As of January 16, 2026, Caribou Biosciences, Inc.’s stock price is $1.460, which is down 6.41% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Caribou Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.